# Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

> **NCT01431521** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 31 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** MK-4074 200 mg
- **DRUG:** Placebo for MK-4074
- **DRUG:** Pioglitazone hydrochloride 30 mg
- **DRUG:** Placebo for pioglitazone hydrochloride

## Key facts

- **NCT ID:** NCT01431521
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-26
- **Primary completion:** 2012-09-18
- **Final completion:** 2012-10-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2018-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01431521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01431521, "Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT01431521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*